Purchase of Shares and PDMR Shareholding

18 June 2021

Diaceutics PLC

("Diaceutics" or "the Company")

Purchase of Shares and PDMR Shareholding

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company for precision testing announces that on 17 June 2021, Deborah Davis, the Chair of Diaceutics, purchased a total of 27,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares"). Of these, 20,000 were purchased at a price of 130 pence per Ordinary Share, and 7,000 at a price of 128 pence per Ordinary Share. As a result of the purchase, Deborah's shareholding is 27,000 Ordinary Shares, representing approximately 0.03% of the Company's issued share capital.

Enquiries:

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.